Billable / Specific Code
ICD-10-CM D64.81 is the diagnosis code for Anemia due to antineoplastic chemotherapy. This code falls under the section "Aplastic and other anemias and other bone marrow failure syndromes" within Chapter 3 â Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism (D50-D89). It is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. Medical coders and healthcare providers use this code to document and classify diagnoses in electronic health records, insurance claims, and clinical databases.
The following conditions are not included in D64.81. If the patient has both, code each condition separately:
Understanding where D64.81 sits in the ICD-10-CM classification helps ensure proper coding:
Yes, D64.81 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes.
D64.81 is the ICD-10-CM diagnosis code for "Anemia due to antineoplastic chemotherapy". It is used by healthcare providers to classify and document this condition in medical records and insurance claims.
The parent code of D64.81 is D64.8 ("Other specified anemias"). D64.81 provides a more specific classification within this category.
D64.81 is located in Section D60-D64 â "Aplastic and other anemias and other bone marrow failure syndromes" within Chapter 3 of the ICD-10-CM Tabular List.
Use D64.81 when the patients documented diagnosis matches "Anemia due to antineoplastic chemotherapy" and the clinical documentation supports this level of specificity. Always verify with the latest ICD-10-CM guidelines and payer requirements.
The ICD-10-CM code for Anemia due to antineoplastic chemotherapy is D64.81.
Yes, D64.81 can be used as a primary diagnosis code since it is billable and specific.
D64.81 is in Chapter 3 of the ICD-10-CM Tabular List.
Yes, D64.81 is a valid ICD-10-CM code for the 2026 fiscal year, subject to official CMS updates.